Publications by authors named "Jennell Palaia"
Article Synopsis
- Nivolumab combined with relatlimab and ipilimumab has been approved for treating advanced melanoma based on clinical trials, but no direct comparison of the two treatments existed, leading to an indirect comparison using patient-level data.
- The study utilized inverse probability of treatment weighting to balance patient characteristics and compared various outcomes like progression-free survival and treatment-related adverse events, finding both regimens had similar efficacy.
- Nivolumab plus relatlimab showed a better safety profile, with fewer severe side effects and treatment discontinuations than nivolumab plus ipilimumab, although some subgroup analyses suggested varying results.
Objectives: Nivolumab is approved as adjuvant therapy for resected stage III/IV melanoma based on the phase 3 CheckMate 238 trial. This analysis compared outcomes from CheckMate 238 with those from the real-world Flatiron Health electronic health record-derived de-identified database in patients with resected stage III melanoma (per AJCC-8) treated with adjuvant nivolumab.
Materials: Outcomes included baseline characteristics, overall survival (OS) in the CheckMate 238 cohort (randomization until death or last known alive), and real-world overall survival (rwOS) in the Flatiron Health cohort (nivolumab initiation until death or data cutoff).
Article Synopsis
- Venous thromboembolism (VTE) is a major health concern for lung cancer patients, particularly those undergoing systemic therapies like chemotherapy, whose risks need to be assessed alongside newer treatments like immune checkpoint inhibitors (ICIs).
- A study analyzed data from 2299 advanced non-small cell lung cancer patients to compare the incidence of VTE across three treatment types: ICI-based, chemo-based, and combined ICI+chemo therapies.
- The findings showed that the ICI-based group had a 26% lower risk of VTE compared to those on chemotherapy alone, highlighting the potential benefits of ICIs in managing VTE risks while treating lung cancer.